The FDA Just Approved a New Allergy Pill for Dogs — Here's What Every Owner Should Know About NUMELVI

What Is NUMELVI — And Why Should Dog Owners Care?

On February 25, 2026, the U.S. Food and Drug Administration (FDA) approved NUMELVI (atinvicitinib tablets), a groundbreaking new medication for dogs suffering from allergic dermatitis — the chronic itching, scratching, and skin irritation that plagues millions of pups nationwide.

Developed by Merck Animal Health, NUMELVI is the first and only second-generation Janus kinase (JAK) inhibitor approved for dogs in the United States. If that sounds like a mouthful, here's the simple version: it's a once-daily pill that stops the itch — fast — while being gentler on your dog's immune system than older options.

"Merck Animal Health is proud to introduce NUMELVI, our latest advancement geared at rapidly controlling pruritus associated with allergic dermatitis, a common condition that causes distress for so many pets and pet owners," said Christine McKinney, DVM, DACVD, Senior Professional Services Veterinarian at Merck Animal Health.

The product is expected to be available at veterinary clinics and hospitals nationwide beginning in spring 2026 — just in time for allergy season.

Why This Matters: Dog Allergies Are Incredibly Common

If your dog has ever spent a night chewing their paws, rubbing their face on the carpet, or scratching until their skin turns raw, you're not alone. Skin conditions account for up to 20% of all cases seen in general veterinary practice, according to Merck Animal Health. Canine atopic dermatitis — the fancy term for environmental allergies in dogs — is estimated to affect anywhere from 3% to 15% of all dogs, according to research published in the National Institutes of Health.

And just like human allergies, the problem appears to be getting worse. Across species, the prevalence of atopic dermatitis is on the rise, researchers report.

For dog owners, the fallout goes beyond itchy skin. Allergic dermatitis can significantly impact quality of life — for both dogs and their humans. Think interrupted sleep from constant scratching, secondary skin infections from broken skin, emotional distress, and expensive vet bills that stack up over time.

How NUMELVI Compares to Apoquel and Cytopoint

If your dog already takes allergy medication, you've likely heard of Apoquel (oclacitinib) or Cytopoint — the two treatments that have dominated the canine allergy market for years. Both are made by Zoetis and have helped millions of dogs. But NUMELVI brings some notable upgrades to the table.

NUMELVI vs. Apoquel

Apoquel was the first JAK inhibitor approved for dogs back in 2013. It targets JAK1 and JAK3 pathways, and it works — but it's a first-generation drug. NUMELVI is at least 10 times more selective for JAK1 than JAK2, JAK3, or TYK2, according to Merck's data. That higher selectivity means it can minimize interference with the other immune functions your dog's body relies on.

There are practical differences, too:

• Age requirement: Apoquel is approved for dogs 12 months and older. NUMELVI can be used in dogs as young as 6 months — a game-changer for puppy owners dealing with early-onset allergies.
• Dosing: Apoquel requires twice-daily dosing for the first two weeks, then once daily. NUMELVI is once daily from the start.
• Vaccinations: NUMELVI has been shown to have no impact on immune response to vaccination, so there's no need to adjust your dog's vaccine schedule.
• Size range: NUMELVI works for dogs as small as 4.4 pounds, and most dogs need only one or half a tablet.

NUMELVI vs. Cytopoint

Cytopoint is an injectable antibody treatment administered at the vet's office every 4 to 8 weeks. It works well for many dogs, but it requires regular vet visits — which can be inconvenient and costly. NUMELVI offers the simplicity of a daily pill you give at home, with itch relief starting from the very first dose.

"Second-generation JAK inhibitors are already considered the standard of care in human health, and NUMELVI brings that same advanced approach to veterinary medicine," said Tim Kowalski, Distinguished Scientist at Merck Animal Health.

What Dog Owners Should Know Before Asking Their Vet

Before you call your vet to request a prescription, here's what you need to know:

Who Can Take NUMELVI?

• Dogs 6 months of age and older
• Dogs weighing at least 4.4 pounds (2 kg)
• Dogs diagnosed with allergic dermatitis, including atopic dermatitis

Who Should NOT Take NUMELVI?

• Dogs under 6 months old
• Dogs with serious active infections
• Dogs with a history of recurrent demodicosis (a type of mange caused by mites) — your vet will weigh the risks and benefits
• NUMELVI has not been evaluated in breeding, pregnant, or lactating dogs

Potential Side Effects

Like any JAK inhibitor, NUMELVI may increase susceptibility to certain opportunistic infections, including demodicosis and interdigital furunculosis (those painful bumps between your dog's toes). New growths — both benign and malignant — have been reported in dogs treated with other JAK inhibitors, so your vet will want to monitor your dog during treatment.

The effectiveness and safety of NUMELVI have not been evaluated in a field study beyond 28 days, so long-term data is still emerging.

Spring Allergy Season Is Coming — Here's How to Prepare

The timing of NUMELVI's approval couldn't be better. With spring right around the corner, millions of dogs across the country are about to enter peak allergy season. Tree pollen kicks things off in early spring, followed by grass and weed pollen through summer and into early fall.

Here's how to get ahead of allergy season with your dog:

1. Schedule a vet appointment now. Don't wait until your dog is miserable. Ask about NUMELVI and whether it might be right for your pup when it becomes available this spring.
2. Know the signs. Excessive scratching, licking paws, rubbing the face, red or inflamed skin, recurring ear infections, and hot spots can all signal allergic dermatitis.
3. Keep a symptom diary. Tracking when symptoms flare can help your vet determine whether your dog has seasonal or year-round allergies.
4. Wipe down after walks. A quick wipe of your dog's paws and belly after outdoor time can reduce allergen exposure.
5. Consider your dog's whole picture. Diet, bathing frequency, and environmental factors all play a role in managing allergies long-term.

The Bigger Picture: A Growing Market for Canine Allergy Relief

NUMELVI isn't the only new player in the space. Zenrelia (ilunocitinib), made by Elanco, is another newer JAK inhibitor that's been available in several countries for over a year. The canine allergy treatment market is rapidly evolving, giving veterinarians and pet owners more tools than ever to manage this frustrating condition.

As veterinary dermatologist discussions increasingly compare these medications, the consensus is clear: having more options means better, more personalized care for every dog. Your vet can now tailor treatment based on your dog's age, size, health history, and specific allergy profile.

The Bottom Line

If your dog suffers from allergic dermatitis, the FDA's approval of NUMELVI is genuinely good news. It represents a meaningful step forward in how we treat one of the most common — and most frustrating — conditions in dogs. With its targeted approach, lower age requirement, simplified dosing, and no interference with vaccinations, NUMELVI gives veterinarians a powerful new option heading into allergy season.

Talk to your veterinarian about whether NUMELVI might be right for your dog. And in the meantime, keep an eye out for those early allergy signs — because the best time to start a treatment plan is before the itching begins.

Looking for more ways to keep your dog happy and healthy? Sidewalk Dog is your go-to resource for dog-friendly adventures, expert advice, and everything that makes life with your pup a little more fun. Explore our city guides to find dog-friendly spots near you.